A leadership shakeup at what was once Europe's most valuable company is likely to be cemented Friday as Novo Nordisk 's controlling shareholder tightens it's grip on the weight-loss drugmaker, even as minority shareholders express discontent. Novo has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence waning, as its role as the leading player in the highly lucrative weight-loss space is being called into question. The maker of diabetes and